Antibiotic activity of the rifabutin nanoparticle formulation
- 1 аспирант, кафедра биологической химии, лечебный факультет, Первый Московский государственный медицинский университет им. И.М. Сеченова
- 2 к.х.н, вед. науч. сотрудник, Всероссийский научный центр молекулярной диагностики и лечения (Москва)
- 3 вед. науч. сотрудник, Всероссийский научный центр молекулярной диагностики и лечения
- 4 к.б.н, вед. науч. сотрудник, Всероссийский научный центр молекулярной диагностики и лечения
- 5 член-корр. РАМН, д.х.н., профессор, зав. кафедрой биологической химии, Первый Московский государственный медицинский университет им. И.М. Сеченова
Abstract
The article is devoted to the actual problem of the creation of high-performance, low-toxic anti-tuberculosis drugs that can overcome the acquired drug resistance. The article provides a description of nanoparticle antibiotic rifabutin, that is used for resistant tuberculosis, formulation receipt. The resulting comparative evaluation of the antimicrobial nanosomal activity of established pharmaceutical form and free substance showed a significant increase in the efficiency of the developed drug. The attention is paid to the necessity of a search for effective methods to increase the effectiveness of pharmaceuticals, capable to accelerate fight against tuberculosis at the source of infection.
How to cite
Кузнецова И.Г., Воронцов Е.А., Кузнецов С.Л., Барсегян Г.Г., Северин С.Е. Антибиотическая активность наносомальной формы рифабутина // Вопросы биологической, медицинской и фармацевтической химии. 2013. № 8. С. 48–52.
References
- Dhople A.M., Ibanes M.A. In vitro activity of three new fluoroqinolones and synergy with ansamycins against Mycobacterium leprae // J. Antimicrob Chemother. 1993. V. 32. R. 445-449.
- Francis J. Drug-resistand Tuberculosis: a survival guide for clinicias / San Francisco, Curry National Tuberculosis Center and California Department of Health Services. 2004.
- Moghimi S. M., Hunter A.C., Murrey J.C. Long-circulating and targetspecific nanoparticles: theory to practice // Pharmacol. Rev. 2001. V. 53. P. 283-318.
- Monography. Mycobutin, rifabutin capsules, USP
- National Committee for Clinical Laboratory Standards. Performance Standards for antimicrobial susceptibility testing 13th and 14th informational supplement. NCCLS document M100-S13.2003 and document M100-S14. 2004. Wayne, PA.
- National Committee for Clinical Laboratory Standards. 1997. Method for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Approved Standard M-7-A4 / 4th ed. Villanova.
- Shafran S., Deschenes J., Miller M. et al. Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin, and ethambutol // N Engl J. Med. 1994. V. 330. P. 438-439.
- Kukushkin Ju.N. Dimetilsul'foksid ? vazhnejshij aprotonny'j rastvoritel' // Sorosovskij obrazovatel'ny'j zhurnal. 1997. № 9. S. 54-56.
- Opredelenie chuvstvitel'nosti mikroorganizmov k antibakterial'ny'm preparatam. Metodicheskie ukazaniya. MUK 4.2.1890-04. 2004.
- Hillaireau H., Couvreur P. Nanocarriers? entry into the cell: relevance to drug delivery // Cellular and Molecular Life Sciences. 2009. V.66. P. 2873-2896.
- Patent № 2327457 (RF). Lekarstvennoe sredstvo na osnove rifabutina, preparat protivomikrobnogo dejstviya, soderzhashhij nanochasticzy', i sposob ego polucheniya / E.S. Severin, L.N. Kryukov, I.E. Zy'kova, G.G. Barsogyan, E.A. Voronczov, S.L. Kuzneczov, T.A. Pomazkova, S.G. Gumakov.
- Pul Ch., Oue'ns F. Mir materialov i texnologij. Nanotexnologii. M.: Texnosfera. 2006. S. 319-327.
- Shtil'man M.I. Polimery' mediko-biologicheskogo naznacheniya. M.: Akademkniga. 2006. 400 s.
- Klimova O.V., Voronczov E.A., Semenov S.Ju., Severin S.E., Severin E.S. Vliyanie nekotory'x parametrov sinteza na svojstva nanosomal'noj lekarstvennoj formy', poluchaemoj na osnove sopolimerov molochnoj i glikolevoj kislot // Voprosy' biologicheskoj, mediczinskoj i farmaczevticheskoj ximii. 2010. № 4. S. 27-33.